Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Telomerase-dependent gene therapy.

Thomas Wirth1, Florian Kühnel, Stefan Kubicka

  • 1Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Carl Neuberg Str. 1, 30625 Hannover, Germany.

Current Molecular Medicine
|June 25, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting of p53-Transcriptional Dysfunction by Conditionally Replicating Adenovirus Is Not Limited by p53-Homologues.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

A preclinical model for the identification of therapeutically active transgenes in local cancer immunotherapy.

Oncoimmunology·2025
Same author

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.

Cell death and differentiation·2025
Same author

Risk factors of avascular femoral head necrosis after a pediatric femoral neck fracture: a 15-year follow up and an adjustment to the Delbet classification.

European journal of trauma and emergency surgery : official publication of the European Trauma Society·2025
Same author

Synthesis and Reactivity of Six-Membered Cyclic Diaryl λ<sup>3</sup>-Bromanes and λ<sup>3</sup>-Chloranes.

Angewandte Chemie (International ed. in English)·2025
Same author

Oncolytic viruses expressing MATEs facilitate target-independent T-cell activation in tumors.

EMBO molecular medicine·2025
Same journal

Corrigendum to: Sortilin as a Culprit in the Atherosclerosis Plaque Progression: Evidence from Clinical and Experimental Studies.

Current molecular medicine·2026
Same journal

Dynamic Expression of Fibroblast Activation Protein (FAP) During Chronic Pancreatitis (CP) Progression in Mice and Evaluation of FAP-targeted Tracers for Early CP Diagnosis.

Current molecular medicine·2026
Same journal

Causal Relationship Between 91 Inflammatory Factors and Gastritis: A Two-Sample Bidirectional Mendelian Randomization Study.

Current molecular medicine·2026
Same journal

Therapeutic Potential of Pistacia Atlantica Gum in Aspirin-Induced Peptic Ulcers: A Dose-Dependent Approach to Mucosal Protection and Hepatorenal Safety.

Current molecular medicine·2026
Same journal

Identification and Characterization of MicroRNAs Associated with Borax-mediated Anti-tumor Activity through High-throughput Technology.

Current molecular medicine·2026
Same journal

Broad-Spectrum Vaccines: Challenges and Opportunities (A Systematic Review).

Current molecular medicine·2026
See all related articles

Adenoviral gene therapy uses the hTERT promoter for tumor specificity. New conditionally replicative adenoviral vectors (CRADs) enhance cancer treatment efficacy by replicating within tumors.

Area of Science:

  • Oncology
  • Gene Therapy
  • Virology

Background:

  • Adenovirus-mediated gene therapy is a promising cancer treatment.
  • Tumor-specific promoters enhance oncotropic vector specificity.
  • The hTERT promoter targets telomerase, prevalent in ~90% of tumors.

Purpose of the Study:

  • To review advances in telomerase-based gene therapy for cancer.
  • To discuss the development and potential of oncotropic adenoviral vectors.
  • To explore combinative strategies for enhanced clinical application.

Main Methods:

  • Development of first-generation adenoviral vectors with hTERT promoter.
  • Creation of telomerase-dependent conditionally replicative adenoviral vectors (CRADs).
  • Evaluation of combinative strategies with chemotherapy, radiotherapy, and antiangiogenesis.

Related Experiment Videos

Main Results:

  • hTERT promoter directs transgene expression specifically in tumors.
  • First-generation vectors showed therapeutic potential but were limited to initial cells.
  • CRADs combine tumor specificity with viral lytic efficacy.

Conclusions:

  • Telomerase-based gene therapy offers significant potential for cancer treatment.
  • CRADs represent a promising advancement in oncotropic vector development.
  • Future research should focus on clinical translation and combination therapies.